David P. Hochman - 12 Feb 2026 Form 4 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Role
Chief Executive Officer and Chairperson, Director
Signature
/s/ Andrew Taylor, Attorney-in-Fact
Issuer symbol
OBIO
Transactions as of
12 Feb 2026
Net transactions value
$0
Form type
4
Filing time
13 Feb 2026, 17:00:30 UTC
Previous filing
12 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hochman David P Chief Executive Officer and Chairperson, Director C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE /s/ Andrew Taylor, Attorney-in-Fact 13 Feb 2026 0001292834

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OBIO Common Stock, par value $0.0001 per share ("Common Stock") Award $0 +504,000 +88% $0.000000 1,076,467 12 Feb 2026 Direct F1
holding OBIO Common Stock 439,482 12 Feb 2026 By the DPH 2008 Trust
holding OBIO Common Stock 2,000 12 Feb 2026 By the Solomon Ascher Hochman 2019 Trust
holding OBIO Common Stock 2,000 12 Feb 2026 By the Hannah Hochman 2019 Trust
holding OBIO Common Stock 2,000 12 Feb 2026 By the Judah Herman Hochman 2019 Trust
holding OBIO Common Stock 3,140 12 Feb 2026 By the NSH 2008 Family Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 25% of the shares will vest 18 months after February 12, 2026 (the "Issue Date"), (ii) 25% of the shares will vest 24 months after the Issue Date, (iii) 25% of the shares will vest 30 months after the Issue Date and (iv) 25% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates.

Remarks:

Chief Executive Officer and Chairperson